Breast Cancer Adjuvant Therapy Cardiac Risk Stratification

Breast Cancer Adjuvant Therapy Cardiac Risk Stratification: Explanation and Clinical Context This tool estimates the risk of developing cardiotoxicity in breast cancer patients receiving adjuvant therapy, particularly with anthracyclines and/or trastuzumab. Risk factors include advanced age, lower baseline left ventricular ejection fraction (LVEF), presence of hypertension or diabetes, and exposure to cardiotoxic agents. The calculated risk score stratifies patients into Low, Intermediate, or High risk categories, guiding clinicians in monitoring frequency, preventive strategies, and therapeutic adjustments.

This approach is based on validated models and studies including Ezaz et al., 2013, which used clinical and treatment-related factors to predict trastuzumab-related cardiotoxicity, and Cardinale et al., 2015, for anthracycline-related risk.